[Experience of using tocilizumab in patients with COVID-19 from a referral hospital in Peru]

Rev Peru Med Exp Salud Publica. 2021 Apr-Jun;38(2):360-362. doi: 10.17843/rpmesp.2021.382.6756. Epub 2021 Aug 30.

[Article in Spanish]

Authors

Antonio Morales-Avalos¹, Kenneth G Vargas-Ponce¹, Jose J Idrogo-Alfaro¹, Juan A Salas-López^{1

2}, Félix K Llanos-Tejada^{1

3}

Affiliations

¹ Servicio de Neumología, Hospital Nacional Dos de Mayo, Lima, Perú.
² Facultad de Medicina Humana, Universidad Nacional Mayor de San Marcos, Lima, Perú.
³ Instituto de Investigación de Ciencias Biomédicas, Universidad Ricardo Palma Lima, Perú.

PMID: 34468589
DOI: 10.17843/rpmesp.2021.382.6756

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
COVID-19 Drug Treatment*
Hospitals
Humans
Peru
Referral and Consultation
SARS-CoV-2

Substances

Antibodies, Monoclonal, Humanized
tocilizumab